抗胸腺细胞球蛋白联合环孢素与雄激素及造血生长因子治疗重型再生障碍性贫血的临床研究

Clinical research on treatment of severe aplastic anemia by anti-thymocyte globulin, cyclosporine A, androgenic hormone and hemopoietic growth factor

目的 观察抗胸腺细胞球蛋白（ATG）联合环孢素、雄激素及造血生长因子治疗重型再生障碍性贫血（SAA）的疗效及安全性. 方法 2007年1月至2009年12月应用ATG联合环孢素、雄激素及造血生长因子对21例SAA患者进行治疗,检测其治疗前后血象及骨髓象的变化,分析临床疗效. 结果 21例SAA患者中,基本治愈3例,缓解4例,明显进步7例,无效5例,死亡2例;总有效率为66.7%. 结论 联合应用ATG、环孢素、雄激素及造血生长因子治疗SAA,疗效肯定,不良反应相对较轻,值得临床广泛应用,是SAA长期无病生存的重要治疗方法.

Objective To observe the effectiveness and safety of the therapy of severe aplastic anemia （SAA）with antithymocyte globulin（ALG）association cyclosporine,androgenic hormone and hemopoietic growth factor Methods Clinical data of 21 patients with severe aplastic anemia who received the treatment of ALG,cyclosporine,androgenic hormone and hemopoietic growth factor from January 2003 to December 2007 were analyzed retrospectively. Results Of the 21 patients,3 persons were nearly cured and 4 were relieved.Seven individuals were improved and 14 patients were invalid.The overall effective rate was 66.7%. Conclusions The combination therapy of ATG,cyclosporin A,androgenic hormone and hemopoietic growth factor is effective and safe.It＇s an important therapy on SAA.